iPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTAC

iPGDAC，CPTAC 综合蛋白质组数据分析中心

• 批准号: 9764289
• 负责人: Bing Zhang
• 金额: $ 93.33万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-20 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9764289
• 关键词: Address; Aftercare; Area; Biological Assay; Biological Markers; Breast; Cancer Biology; Clinic; Clinical; Clinical Treatment; Collaborations; Colorectal Cancer; Colorectal Neoplasms; Complex; Computer Analysis; Computing Methodologies; Cultured Cells; DNA Sequence Alteration; Data; Data Analyses; Drug Combinations; Drug effect disorder; Drug resistance; Galaxy; Genome; Genomics; Goals; Human; Imagery; Individual; Informatics; Institutes; Journals; Knowledge; Leadership; Malignant Neoplasms; Malignant neoplasm of ovary; Mammary Neoplasms; Manuscripts; Mass Spectrum Analysis; Medicine; Multiomic Data; Nature; Ovarian; Paper; Pathway Analysis; Pathway interactions; Patients; Peptides; Phase; Pre-Clinical Model; Proteins; Proteomics; Publishing; Reporting; Research Personnel; Resources; Sampling; Specific qualifier value; Specimen; System; Systems Analysis; Technology; The Cancer Genome Atlas; Translations; Universities; Variant; Visualization software; Work; Xenograft procedure; acquired drug resistance; base; biomarker identification; cancer therapy; cancer type; candidate identification; candidate marker; clinically relevant; college; computerized tools; data format; data integration; genomic data; hands on instruction; improved; malignant breast neoplasm; novel; oncology; outcome forecast; ovarian neoplasm; predictive modeling; programs; proteogenomics; response; statistics; targeted biomarker; therapeutic target; tool; tumor; user-friendly; virtual; web interface

Project Summary Proteogenomic characterization of human tumors seeks to explain how complex genomic alterations drive the hallmarks of cancer through mass spectrometry based proteomic analysis. The field has been accelerated by the Clinical Proteomic Tumor Analysis Consortium (CPTAC) who performed proteomic analyses for breast, colorectal and ovarian tumors and integrated the data with genomic information provided by the Cancer Genome Atlas (TCGA). Our Vanderbilt team conducted the colorectal cancer study and published the first paper on proteogenomic characterization of human cancer in the journal Nature. Data analysis approaches pioneered by us also were used in the CPTAC breast and ovarian cancer studies. Results from all three studies successfully demonstrated the value of integrative proteogenomic analyses in achieving a more complete understanding of cancer biology. Based on this proof of concept, the new CPTAC program seeks to expand the proteogenomic approach to more cancer types and to diverse types of samples including pre- and post-treatment clinical specimens, cultured cells, and patient-derived xenografts (PDXs). This application proposes an integrative proteogenomic data analysis center (iPGDAC) built on our established expertise and resources. The overarching goal of the iPGDAC is to analyze data generated by CPTAC and related resources to better understand cancer biology and to improve cancer treatment. To comprehensively exploit all CPTAC data, we propose three tiers of data analysis. Tier 1 analyses will integrate proteomic and genomic data generated from individual studies. These analyses will identify variant peptides and proteins as candidate biomarkers or therapeutic targets, will predict patient prognosis and response to therapy based on multi-omics data, and will reveal mechanisms of drug action and acquired drug resistance to drive rational drug combinations. Tier 2 analyses will integrate data between preclinical models and human tumors to enable effective translation of experimental findings to the clinic. Tier 3 analyses will integrate data across different cancer types to identify common and cancer type-specific protein signatures and networks. We will make our computational tools and analysis results publically available in two integrated proteogenomic data analysis systems, which will facilitate the collaborative identification of candidate biomarkers by all CPTAC investigators and will broaden the impact of the CPTAC program. The iPGDAC brings to the CPTAC network a fully integrated, completely established program with expertise in all the critical areas specified by the RFA. We have a proven track record of leadership in computational proteogenomics and successful collaboration in the CPTAC network, and we expect to broadly advance the field through this project.

项目摘要 人类肿瘤的蛋白质基因组特征试图解释复杂的基因组变化如何 通过基于质谱学的蛋白质组学分析来驱动癌症的特征。这块田地一直是 由进行蛋白质组学的临床蛋白质组肿瘤分析联盟(CPTAC)加速 对乳腺、结直肠和卵巢肿瘤进行分析，并将数据与提供的基因组信息相结合 由癌症基因组图谱(TCGA)提供。我们的Vanderbilt团队进行了结直肠癌研究， 在《自然》杂志上发表了第一篇关于人类癌症蛋白质基因组特征的论文。数据 我们开创的分析方法也被用于CPTAC的乳腺癌和卵巢癌研究。结果 从所有这三项研究中成功地证明了综合蛋白质基因组分析在实现 对癌症生物学有了更全面的了解。基于这一概念证明，新的CPTAC计划 寻求将蛋白质基因组学方法扩展到更多的癌症类型和不同类型的样本，包括 治疗前后的临床标本、培养细胞和患者来源的异种移植物(PDX)。这 应用程序建议在我们已建立的基础上建立一个综合蛋白质基因组数据分析中心(IPGDAC) 专业知识和资源。IPGDAC的首要目标是分析CPTAC产生的数据和 相关资源，以更好地了解癌症生物学和改进癌症治疗。要全面 利用CPTAC的所有数据，我们提出了三层数据分析。一级分析将整合蛋白质组学和 从个体研究中产生的基因组数据。这些分析将鉴定变异肽和蛋白质为 候选生物标志物或治疗靶点，将基于以下因素预测患者预后和治疗反应 多组学数据，并将揭示药物作用机制和获得性耐药，以推动合理用药 组合。第二级分析将整合临床前模型和人类肿瘤之间的数据，以实现 将实验结果有效地转化为临床。第3层分析将跨不同的 癌症类型识别常见的和癌症类型特定的蛋白质签名和网络。我们将使我们的 在两个综合蛋白质组数据分析中公开的计算工具和分析结果 系统，这将促进CPTAC所有调查人员协作识别候选生物标记物 并将扩大CPTAC计划的影响。IPGDAC为CPTAC网络带来了全面的 在RFA指定的所有关键领域拥有专业知识的完整、完整的计划。我们 在计算蛋白质组学领域具有公认的领导地位，并在 CPTAC网络，我们希望通过这个项目广泛推进这一领域。